|
|
LONDON, UK / ACCESSWIRE / March 16, 2022 / Hemogenyx Pharmaceuticals plc LSE:HEMO, the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that it has achieved proof of concept "POC" for its Chimeric Bait Receptor "CBR" platform technology. The Company has filed a seminal provisional patent application protecting its... Lire le communiqué |
|
| |
|
| |
|
|
LONDON, UK / ACCESSWIRE / February 16, 2022 / Hemogenyx Pharmaceuticals plc "Hemogenyx Pharmaceuticals" or the "Company" LSE:HEMO, the biopharmaceutical group developing new therapies and treatments for blood diseases, has received notification from the Food and Drugs Administration "FDA" that the proposed preInvestigational New Drug "preIND" meeting... Lire le communiqué |
|
| |
|
| |
|
|
Hemogenyx Pharmaceuticals plc"Hemogenyx Pharmaceuticals" or the "Company"Hemogenyx Pharmaceuticals Partnership with Selexis SA to Advance CDX DevelopmentHemogenyx Pharmaceuticals and Selexis SA "Selexis" will leverage Selexis SUREtechnology Platform™ of protein expression technologies and modular workflows to advance the Companys acute myeloi... Lire le communiqué |
|
| |
|
| |
|
|
LONDON, UK / ACCESSWIRE / January 5, 2022 / Hemogenyx Pharmaceuticals plc LSE:HEMO, the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce its participation in the H.C. Wainwright Bioconnect Conference, in which the Company will be featured as a presenting company. The conference will be held on a virtual platform from January 1013, 2022.As... Lire le communiqué |
|
| |
|
| |
|
|
Partnership with WuXi Advanced Therapies to manufacture lentiviral vectors for phase I trial of cutting edge HEMOCART programmeLONDON, UK / ACCESSWIRE / December 20, 2021 / Hemogenyx Pharmaceuticals will leverage WuXi Advanced Therapies "WuXi ATU" plasmid and lentiviral vector manufacturing platforms, including integrated testing, to accelerate HEMOCART programme for acute myeloid... Lire le communiqué |
|
| |
|
| |
|
|
LONDON, UK / ACCESSWIRE / December 13, 2021 / Hemogenyx Pharmaceuticals plc LSE:HEMO, the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce significant progress in relation to moving its lead product candidate Chimeric Antigen Receptor "CAR" Tcells "HEMOCART" toward clinical trials. The Company has applied for a... Lire le communiqué |
|
| |
|
| |
